[Investigation of adrenal function with corticotrophin-(1-23)-tricosipeptide-amide (author's transl)].
The new peptide corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S) was shown to be useful in the assessment of adrenal function. Both in normal subjects and patients with adrenal insufficiency, the cortisol releasing capacity could be better evaluated with a dosage of 0.5 mg than with 0.25 mg. There were no obvious side effects induced by corticotrophin-(1-23)-tricosipeptide-amide.
D000304:Adrenal Cortex Function Tests / Q000379:methods*; D000309:Adrenal Insufficiency / Q000097:blood; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage; D010912:Pituitary-Adrenal Function Tests / Q000379:methods*
D010455:Peptides; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone
Prüfung der Nebennierenrindenfunktion mit Kortikotropin-(1-23)-Trikosipeptid-amid